Navigation Links
Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
Date:12/31/2008

CORONA, Calif., Dec. 31 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration to market its over-the-counter Nicotine Polacrilex Gum USP, coated mint flavor, in the 2 mg and 4 mg strengths.

Nicotine Polacrilex Gum, coated mint flavor, is the generic equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette (R) fresh mint gum, which is used as an aid to smoking cessation. The market for over-the-counter nicotine gum had annual sales of over $300 million for the twelve months ending September 2008, according to IRI sales data. Watson will make the product available to customers in early January 2009.

"The approval of our mint flavored, coated nicotine gum is a significant addition to our line of generic smoking cessation products," said Paul Bisaro, Watson's President and Chief Executive Officer. "We also have applications pending at FDA for additional flavors and look forward further enhancing our line of smoking cessation products."

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by third parties; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.

Nicorette (R) is a registered trademark of GlaxoSmithKline Consumer Healthcare.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
2. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
3. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
4. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
5. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
6. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
7. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
8. Watson Pharmaceuticals Reports Third Quarter 2008 Results
9. Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
10. Older Workers Worried About Promised Medicare and Social Security Benefits, Watson Wyatt Survey Finds
11. Watson Wyatt Identifies Trends for Benefits Open Enrollment Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the Cowen and Company 37 th ... Copley Place on Tuesday, March 7, 2017 at 11:20 ... of the presentation can be accessed at http://wsw.com/webcast/cowen38/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia Drugs ... ... Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks ... What are the key drugs marketed for ... Hemophilia market? What are the unit prices and annual ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
Breaking Medicine Technology: